Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done

In recent years, advances of anticancer and supportive therapies have determined a gradual improvement in survival rates and patients’ general conditions in metastatic gastric cancer (mGC), allowing them to receive further treatments. The choice of treatment is driven by performance status, age, sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Mare, Marzia, Memeo, Lorenzo, Colarossi, Cristina, Giuffrida, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497544/
https://www.ncbi.nlm.nih.gov/pubmed/36135075
http://dx.doi.org/10.3390/curroncol29090506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497544/
https://www.ncbi.nlm.nih.gov/pubmed/36135075
http://dx.doi.org/10.3390/curroncol29090506

Ejemplares similares